Literature DB >> 26655630

Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets.

Andrew J Broadbent1, Celia P Santos1, Amanda Anafu1, Eckard Wimmer2, Steffen Mueller2, Kanta Subbarao3.   

Abstract

Codon-pair bias de-optimization (CPBD) of viruses involves re-writing viral genes using statistically underrepresented codon pairs, without any changes to the amino acid sequence or codon usage. Previously, this technology has been used to attenuate the influenza A/Puerto Rico/8/34 (H1N1) virus. The de-optimized virus was immunogenic and protected inbred mice from challenge. In order to assess whether CPBD could be used to produce a live vaccine against a clinically relevant influenza virus, we generated an influenza A/California/07/2009 pandemic H1N1 (2009 pH1N1) virus with de-optimized HA and NA gene segments (2009 pH1N1-(HA+NA)(Min)), and evaluated viral replication and protein expression in MDCK cells, and attenuation, immunogenicity, and efficacy in outbred ferrets. The 2009 pH1N1-(HA+NA)(Min) virus grew to a similar titer as the 2009 pH1N1 wild type (wt) virus in MDCK cells (∼10(6)TCID50/ml), despite reduced HA and NA protein expression on western blot. In ferrets, intranasal inoculation of 2009 pH1N1-(HA+NA)(Min) virus at doses ranging from 10(3) to 10(5) TCID50 led to seroconversion in all animals and protection from challenge with the 2009 pH1N1 wt virus 28 days later. The 2009 pH1N1-(HA+NA)(Min) virus did not cause clinical illness in ferrets, but replicated to a similar titer as the wt virus in the upper and lower respiratory tract, suggesting that de-optimization of additional gene segments may be warranted for improved attenuation. Taken together, our data demonstrate the potential of using CPBD technology for the development of a live influenza virus vaccine if the level of attenuation is optimized. Published by Elsevier Ltd.

Entities:  

Keywords:  Codon pair bias de-optimization; Influenza; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26655630      PMCID: PMC4713281          DOI: 10.1016/j.vaccine.2015.11.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Endonucleolytic cleavage of eukaryotic mRNAs with stalls in translation elongation.

Authors:  Meenakshi K Doma; Roy Parker
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

2.  Adaptation and growth characteristics of influenza virus at 25 degrees c.

Authors:  H F Maassab
Journal:  Nature       Date:  1967-02-11       Impact factor: 49.962

3.  Future influenza vaccines and the use of genetic recombinants.

Authors:  E D Kilbourne
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

4.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Authors:  K M Edwards; W D Dupont; M K Westrich; W D Plummer; P S Palmer; P F Wright
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

5.  RNA polymerase I catalysed transcription of insert viral cDNA.

Authors:  A Zobel; G Neumann; G Hobom
Journal:  Nucleic Acids Res       Date:  1993-08-11       Impact factor: 16.971

6.  The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial.

Authors:  T M Govaert; C T Thijs; N Masurel; M J Sprenger; G J Dinant; J A Knottnerus
Journal:  JAMA       Date:  1994-12-07       Impact factor: 56.272

7.  Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants.

Authors:  Y Z Ghendon; F I Polezhaev; K V Lisovskaya; T E Medvedeva; G I Alexandrova; A I Klimov
Journal:  Infect Immun       Date:  1984-06       Impact factor: 3.441

8.  RNA polymerase I-mediated expression of influenza viral RNA molecules.

Authors:  G Neumann; A Zobel; G Hobom
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

9.  Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine.

Authors:  Grace D Appiah; Lenee Blanton; Tiffany D'Mello; Krista Kniss; Sophie Smith; Desiree Mustaquim; Craig Steffens; Rosaline Dhara; Jessica Cohen; Sandra S Chaves; Joseph Bresee; Teresa Wallis; Xiyan Xu; Anwar Isa Abd Elal; Larisa Gubareva; David E Wentworth; Jacqueline Katz; Daniel Jernigan; Lynnette Brammer
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-05       Impact factor: 17.586

10.  tRNA properties help shape codon pair preferences in open reading frames.

Authors:  J Ross Buchan; Lorna S Aucott; Ian Stansfield
Journal:  Nucleic Acids Res       Date:  2006-02-09       Impact factor: 16.971

View more
  28 in total

1.  Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure.

Authors:  Cyril Le Nouën; Thomas McCarty; Michael Brown; Melissa Laird Smith; Roberto Lleras; Michael A Dolan; Masfique Mehedi; Lijuan Yang; Cindy Luongo; Bo Liang; Shirin Munir; Joshua M DiNapoli; Steffen Mueller; Eckard Wimmer; Peter L Collins; Ursula J Buchholz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

Review 2.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

3.  Tyr82 Amino Acid Mutation in PB1 Polymerase Induces an Influenza Virus Mutator Phenotype.

Authors:  Tadasuke Naito; Kazumasa Shirai; Kotaro Mori; Hidetaka Muratsu; Hiroshi Ushirogawa; Ryosuke L Ohniwa; Kousuke Hanada; Mineki Saito
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

Review 4.  Emergency Services of Viral RNAs: Repair and Remodeling.

Authors:  Vadim I Agol; Anatoly P Gmyl
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-14       Impact factor: 11.056

5.  Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models.

Authors:  Penghui Li; Xianliang Ke; Ting Wang; Zhongyuan Tan; Dan Luo; Yuanjiu Miao; Jianhong Sun; Yuan Zhang; Yan Liu; Qinxue Hu; Fuqiang Xu; Hanzhong Wang; Zhenhua Zheng
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

6.  Development of an RNA Strand-Specific Hybridization Assay To Differentiate Replicating versus Nonreplicating Influenza A Viruses.

Authors:  Genyan Yang; Erin N Hodges; Jörn Winter; Natosha Zanders; Svetlana Shcherbik; Tatiana Bousse; Janna R Murray; A K M Muraduzzaman; Mahbubur Rahman; A S M Alamgir; Meerjady Sabrina Flora; Lenee Blanton; John R Barnes; David E Wentworth; C Todd Davis
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

Review 7.  SARS-CoV-2 vaccines in development.

Authors:  Florian Krammer
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

Review 8.  Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2.

Authors:  Rim Jbeli; Awatef Jelassi
Journal:  EuroMediterr J Environ Integr       Date:  2021-07-04

Review 9.  Altering Compositional Properties of Viral Genomes to Design Live-Attenuated Vaccines.

Authors:  Marianoel Pereira-Gómez; Lucía Carrau; Álvaro Fajardo; Pilar Moreno; Gonzalo Moratorio
Journal:  Front Microbiol       Date:  2021-06-30       Impact factor: 5.640

Review 10.  COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.

Authors:  Muhammad Umer Ashraf; Yeji Kim; Sunil Kumar; Dongyeob Seo; Maryam Ashraf; Yong-Soo Bae
Journal:  Vaccines (Basel)       Date:  2021-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.